GlaxoSmithKline sees third quarter earnings beat forecasts thanks to strong demand for HIV drugs and flu vaccines

Britain's biggest drugmaker saw its sales rise 9 per cent to £6.13billion in the three months to September 30, beating analysts’ consensus forecasts for £6.08billion.